Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. (Q37741534)
Jump to navigation
Jump to search
scientific article published on 11 January 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. |
scientific article published on 11 January 2017 |
Statements
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines (English)
Christian Klein
Inja Waldhauer
Valeria G Nicolini
Tapan Nayak
Claire Dunn
Marije Bolijn
Jörg Benz
Martine Stihle
Sabine Lang
Michaele Roemmele
Thomas Hofer
Erwin van Puijenbroek
David Wittig
Samuel Moser
Oliver Ast
Peter Brünker
Ingo H Gorr
Sebastian Neumann
Maria Cristina de Vera Mudry
Heather Hinton
Flavio Crameri
Jose Saro
Stefan Evers
Christian Gerdes
Marina Bacac
Guus van Dongen
Ekkehard Moessner
11 January 2017
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference